跳至主要内容
临床试验/NCT04574830
NCT04574830已完成不适用

Clinical Survey Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

Ultragenyx Pharmaceutical Inc4 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2020年11月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
18
试验地点
4
主要终点
Urine hexose tetrasaccharide (Hex4): mean and variance

研究概览

简要总结

The primary objective of this study is to evaluate potential biomarkers of GSD III.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
5 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed historical diagnosis of GSD III based on pathogenic mutations in the AGL gene on both alleles or GDE deficiency based on biopsy of liver, muscle, or fibroblasts
  • Willing to comply with all study procedures
  • Willing and able to provide written informed consent. If a minor, willing and able to provide written assent and have a legally authorized representative willing and able to provide written informed consent

排除标准

  • Presence or history of any condition that, in the view of the Investigator, places the subject at high risk of poor study compliance, interferes with study participation, or interferes with the subject's ability to safely or reliably complete the study assessments
  • Use of any IP within 30 days prior to informed consent/assent or at the time of enrollment

结局指标

主要结局

Urine hexose tetrasaccharide (Hex4): mean and variance

时间窗: Up to Day 35

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验